TY - JOUR
T1 - Monoclonal antibody to the HLA class I α3 domain inhibits T cell activation and prolongs cardiac allograft survival in HLA- transgenic mice
AU - Woo, Jacky
AU - Cornejo, Marie Christine
AU - Gao, Lan
AU - Taurog, Joel D
AU - Hammer, Robert E
AU - Buelow, Roland
PY - 1997/6
Y1 - 1997/6
N2 - Antibodies recognizing MHC class I molecules expressed on the surface of T cells have been shown to inhibit T cell responses in vitro. These findings suggested that therapy with such an antibody may prevent rejection and promote graft acceptance. We therefore tested the effect of an anti-HLA class I α3 domain antibody (TP25.99) in vivo using transgenic C57BL/6 mice expressing HLA- B2705. Flow cytometric analysis confirmed the binding of TP25.99 to normal human peripheral blood lymphocytes and to mouse spleen cells, bone marrow cells and thymocytes isolated from hemizygous (+/-) transgenic littermates but not from homozygous (-/-) littermates. TP25.99 inhibited OKT-3-induced, but not PMA+ionomycin-induced, proliferation of human peripheral blood lymphocyte as well as anti-CD3 or Con A-induced proliferation of HLA+ mouse T cells. Both intact monoclonal antibody TP25.99 and TP25.99 Fab inhibited T cell proliferation. Reduced proliferation was associated with suppressed production of interleukin-2 as measured by ELISA. The efficacy of TP25.99 Fab in vivo was evaluated in a heart allograft model. Antibody therapy of (H-2b, B2705+) transgenic recipients of allogeneic Balb/c (H-2(d)) heart grafts prolonged graft survival significantly (MST = 19.8 ± 6.4, p = 0.003) compared to treated (H-2b, B2705-) (MST = 9.17 ± 2.2) or untreated (H-2b, B2705+) (MST = 10.0 ± 2.8) transgenic recipients. This demonstrates that immunomodulation through anti-HLA class I antibody therapy can lead to prolongation of graft survival.
AB - Antibodies recognizing MHC class I molecules expressed on the surface of T cells have been shown to inhibit T cell responses in vitro. These findings suggested that therapy with such an antibody may prevent rejection and promote graft acceptance. We therefore tested the effect of an anti-HLA class I α3 domain antibody (TP25.99) in vivo using transgenic C57BL/6 mice expressing HLA- B2705. Flow cytometric analysis confirmed the binding of TP25.99 to normal human peripheral blood lymphocytes and to mouse spleen cells, bone marrow cells and thymocytes isolated from hemizygous (+/-) transgenic littermates but not from homozygous (-/-) littermates. TP25.99 inhibited OKT-3-induced, but not PMA+ionomycin-induced, proliferation of human peripheral blood lymphocyte as well as anti-CD3 or Con A-induced proliferation of HLA+ mouse T cells. Both intact monoclonal antibody TP25.99 and TP25.99 Fab inhibited T cell proliferation. Reduced proliferation was associated with suppressed production of interleukin-2 as measured by ELISA. The efficacy of TP25.99 Fab in vivo was evaluated in a heart allograft model. Antibody therapy of (H-2b, B2705+) transgenic recipients of allogeneic Balb/c (H-2(d)) heart grafts prolonged graft survival significantly (MST = 19.8 ± 6.4, p = 0.003) compared to treated (H-2b, B2705-) (MST = 9.17 ± 2.2) or untreated (H-2b, B2705+) (MST = 10.0 ± 2.8) transgenic recipients. This demonstrates that immunomodulation through anti-HLA class I antibody therapy can lead to prolongation of graft survival.
UR - http://www.scopus.com/inward/record.url?scp=0030851957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030851957&partnerID=8YFLogxK
U2 - 10.1016/S0966-3274(97)80051-2
DO - 10.1016/S0966-3274(97)80051-2
M3 - Article
C2 - 9269033
AN - SCOPUS:0030851957
SN - 0966-3274
VL - 5
SP - 112
EP - 121
JO - Transplant Immunology
JF - Transplant Immunology
IS - 2
ER -